{
  "meta": {
    "title": "04_Endometrial_Cancer",
    "url": "https://brainandscalpel.vercel.app/04-endometrial-cancer-7a06a8bc.html",
    "scrapedAt": "2025-11-30T06:56:44.584Z"
  },
  "questions": [
    {
      "id": 85220,
      "choices": [
        {
          "id": 209374,
          "text": "Pap smear"
        },
        {
          "id": 209375,
          "text": "Fractional curettage"
        },
        {
          "id": 209376,
          "text": "Transvaginal ultrasound"
        },
        {
          "id": 209377,
          "text": "CA-125"
        }
      ],
      "text": "The investigation of choice in a 55-year-old postmenopausal women who has presented with postmenopausal bleeding is:",
      "unique_key": "Q4520504",
      "question_audio": null,
      "question_video": null,
      "map_id": 34346345,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Fractional curettage The investigation of choice for a 55-year-old postmenopausal woman presenting with postmenopausal bleeding (PMB) is fractional curettage. Postmenopausal bleeding is a significant clinical symptom that requires investigation to rule out underlying pathologies such as endometrial hyperplasia, endometrial carcinoma, or other uterine pathologies. Fractional curettage involves scraping the endometrial lining for histopathological evaluation, which allows for the accurate diagnosis of endometrial carcinoma, a leading cause of PMB. It helps to obtain tissue samples from both the endometrium and the cervix, ensuring that no abnormal tissue is missed in the investigation. This is considered the gold standard in diagnosing endometrial pathology in postmenopausal women presenting with bleeding. Option A: Pap smear A Pap smear is a screening test primarily used to detect cervical cancer and precancerous changes in the cervix. While it is an important test for cervical cancer screening, it is not the first-line investigation for postmenopausal bleeding. The bleeding is more likely to originate from the endometrium or uterus, rather than the cervix, so a Pap smear would not be diagnostic for the cause of bleeding in this context. Therefore, it is not the investigation of choice for postmenopausal bleeding. Option C: Transvaginal ultrasound A transvaginal ultrasound (TVUS) is an important tool in evaluating the endometrium and identifying structural abnormalities, such as fibroids, polyps, or thickened endometrial lining. While TVUS can provide useful information regarding endometrial thickness, it does not definitively diagnose endometrial cancer. For postmenopausal bleeding, a thickened endometrium on ultrasound warrants further investigation with fractional curettage or endometrial biopsy to obtain tissue for histological evaluation. Therefore, although helpful in initial evaluation, TVUS is not the investigation of choice for definitive diagnosis in postmenopausal bleeding. Option D: CA-125 CA-125 is a tumor marker that is primarily used in the diagnosis and management of ovarian cancer. While it can be elevated in conditions such as endometriosis, pelvic inflammatory disease, and uterine cancer, it is not specific enough to be used as a primary diagnostic tool for postmenopausal bleeding. The elevation of CA-125 may be observed in a variety of conditions, including benign ones, and is not useful as a first-line test for investigating postmenopausal bleeding. Therefore, CA-125 is not the investigation of choice for this clinical presentation.",
      "correct_choice_id": 209375,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/38198121705565265/38198121705565265.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/38198121705565265/38198121705565265.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 85221,
      "choices": [
        {
          "id": 209378,
          "text": "Histopathology"
        },
        {
          "id": 209379,
          "text": "Hysterectomy"
        },
        {
          "id": 209380,
          "text": "Progesterone"
        },
        {
          "id": 209381,
          "text": "OCP"
        }
      ],
      "text": "A 45 years old lady presented with dysfunctional uterine bleeding. On transvaginal USG thickness of endometrium was found to be 8 mm. What should be the next step in the management of this patient?",
      "unique_key": "Q1422444",
      "question_audio": null,
      "question_video": null,
      "map_id": 34664684,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Histopathology The next step in the management of a 45-year-old woman presenting with dysfunctional uterine bleeding (DUB) and an endometrial thickness of 8 mm on transvaginal ultrasound is to perform histopathological examination. Dysfunctional uterine bleeding refers to abnormal uterine bleeding in the absence of an identifiable structural cause, often due to hormonal imbalances. In women aged 45, it is crucial to rule out any endometrial pathology, including endometrial hyperplasia or endometrial carcinoma, especially if the endometrial thickness is greater than 5 mm in postmenopausal women or greater than 10 mm in premenopausal women. Given the patient’s age and the findings of a moderately thickened endometrium, histopathology (via biopsy) is necessary to assess for underlying pathology, such as endometrial hyperplasia or early carcinoma. This is the gold standard for diagnosing any endometrial abnormalities. Option B: Hysterectomy A hysterectomy is a major surgical intervention that may be considered in cases of severe or persistent DUB that does not respond to other treatments or if there is evidence of malignancy. However, it is not the first step in management, especially in a 45-year-old woman with no definitive signs of malignancy. The first approach should be to establish a clear diagnosis through histopathology before deciding on any surgical procedures. Hysterectomy should only be considered after a diagnosis is made and if other, less invasive options are ineffective or inappropriate. Option C: Progesterone Progesterone therapy is often used to treat DUB, particularly in women who are peri-menopausal or have anovulatory cycles, as it can help regulate the menstrual cycle and decrease bleeding. However, before initiating progesterone therapy, it is crucial to rule out any structural or malignant causes of the bleeding. As the endometrial thickness in this case is 8 mm, it is important to first perform a biopsy or histopathological examination to exclude any serious underlying conditions, such as endometrial hyperplasia or cancer. Starting progesterone without knowing the cause of bleeding might delay the diagnosis of a potentially serious condition. Option D: OCP (Oral Contraceptive Pills) Oral contraceptive pills (OCP) are used in the management of DUB to regulate menstrual cycles, particularly in women with anovulation or irregular bleeding patterns. However, similar to progesterone therapy, OCPs are not recommended as a first-line approach in the presence of a thickened endometrium without ruling out endometrial pathology. The endometrial thickness of 8 mm warrants further investigation to ensure that there is no endometrial hyperplasia or other structural issues. OCPs may be used as a treatment option after a diagnosis is made, but not before evaluating the endometrial condition.",
      "correct_choice_id": 209378,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/42095781705565284/42095781705565284.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/42095781705565284/42095781705565284.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 85222,
      "choices": [
        {
          "id": 209382,
          "text": "Hysterectomy"
        },
        {
          "id": 209383,
          "text": "OCP"
        },
        {
          "id": 209384,
          "text": "Medroxyprogesterone"
        },
        {
          "id": 209385,
          "text": "GnRH analog"
        }
      ],
      "text": "TOC of endometrial hyperplasia without atypia in a 32-year-old female:",
      "unique_key": "Q9284372",
      "question_audio": null,
      "question_video": null,
      "map_id": 34964074,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Medroxyprogesterone The treatment of choice (TOC) for endometrial hyperplasia without atypia in a 32-year-old female is Medroxyprogesterone. Endometrial hyperplasia without atypia is a benign condition characterized by an increase in the number of endometrial glands due to unopposed estrogen stimulation. The primary treatment aims to restore the hormonal balance and prevent progression to endometrial carcinoma. Medroxyprogesterone, a progestin, works by counteracting the effects of estrogen on the endometrium, leading to endometrial shedding and normalization of the lining. It is an effective treatment to reduce the risk of progression while preserving fertility in younger women like this 32-year-old patient. The treatment typically lasts for 6 months, and if the patient responds well, further management may not be required. Option A: Hysterectomy Hysterectomy is a definitive treatment for endometrial hyperplasia that is associated with atypia or if the hyperplasia persists despite medical management. However, endometrial hyperplasia without atypia is not an indication for hysterectomy, especially in a 32-year-old woman who may wish to preserve her fertility. Hysterectomy is typically reserved for cases where the patient does not respond to medical therapy or if there is evidence of progression to endometrial carcinoma. It is a surgical option but is not first-line treatment for endometrial hyperplasia without atypia in this patient. Option B: OCP (Oral Contraceptive Pills) Oral contraceptive pills (OCP) are used for contraception and can also help to regulate menstrual cycles in women with irregular bleeding. However, they are not the first-line treatment for endometrial hyperplasia. While OCPs contain both estrogen and progestin, the progestin content in OCPs is often not high enough to counteract the effects of estrogen on the endometrium effectively. For patients with endometrial hyperplasia without atypia, a stronger progestin therapy like Medroxyprogesterone is typically more effective. OCPs might be considered in some cases for irregular bleeding, but Medroxyprogesterone is more targeted and effective for this condition. Option D: GnRH analog GnRH analogs (like Leuprolide) are used for conditions like endometriosis, fibroids, and preoperative management of certain gynecological conditions. They work by suppressing estrogen production through a mechanism of hypothalamic-pituitary-gonadal axis suppression. However, GnRH analogs are not the first-line treatment for endometrial hyperplasia without atypia. While they can effectively decrease estrogen levels, progestin therapy (like Medroxyprogesterone) is more appropriate and targeted for treating endometrial hyperplasia due to their specific action on the endometrium. Additionally, GnRH analogs have significant side effects due to estrogen suppression, such as bone loss, which makes them less ideal for this patient.",
      "correct_choice_id": 209384,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/67834641705566541/67834641705566541.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/67834641705566541/67834641705566541.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 85223,
      "choices": [
        {
          "id": 209386,
          "text": "Atypical adenomatous hyperplasia"
        },
        {
          "id": 209387,
          "text": "Atrophic endometrium"
        },
        {
          "id": 209388,
          "text": "Adenocarcinoma in situ"
        },
        {
          "id": 209389,
          "text": "Cystic hyperplasia"
        }
      ],
      "text": "The following are precursors of endometrial carcinoma except:",
      "unique_key": "Q9699451",
      "question_audio": null,
      "question_video": null,
      "map_id": 34857789,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Atrophic endometrium The atrophic endometrium is not a precursor to endometrial carcinoma. Atrophy of the endometrium is commonly seen in postmenopausal women due to the lack of estrogen stimulation. It represents a normal aging process and does not predispose to malignancy. Atrophic endometrium is thin and inactive, with a reduction in glandular tissue and minimal cellular activity, making it unlikely to give rise to endometrial carcinoma. Therefore, it is not considered a precursor lesion for endometrial cancer. Option A: Atypical adenomatous hyperplasia Atypical adenomatous hyperplasia (also called endometrial hyperplasia with atypia) is a precursor lesion for endometrial carcinoma. It is characterized by abnormal glandular proliferation in the endometrial lining, with cellular atypia such as increased nuclear-to-cytoplasmic ratio, hyperchromasia, and irregular nuclear contours. This condition increases the risk of progression to endometrial carcinoma, particularly endometrioid adenocarcinoma. Women with atypical adenomatous hyperplasia have a higher risk of developing malignancy, and treatment often involves progestin therapy or hysterectomy to prevent cancer development. Option C: Adenocarcinoma in situ Adenocarcinoma in situ (also referred to as endometrial intraepithelial neoplasia) is a precursor to endometrial carcinoma. It involves the presence of cancerous cells confined to the endometrial glands without invasion of the stroma. It is considered a precancerous condition and often presents as a high-grade precursor lesion to endometrial adenocarcinoma. It requires prompt treatment, usually involving a hysterectomy, to prevent progression to invasive cancer. Option D: Cystic hyperplasia Cystic hyperplasia (also called endometrial hyperplasia with cystic changes) is another precursor to endometrial carcinoma, although it carries a lower risk compared to atypical adenomatous hyperplasia. In cystic hyperplasia, there is abnormal glandular proliferation and cyst formation in the endometrial lining. While not all cases of cystic hyperplasia progress to carcinoma, it is considered a precursor lesion because estrogen stimulation can drive the development of more advanced forms of hyperplasia that can lead to cancer.",
      "correct_choice_id": 209387,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/47347261705566563/47347261705566563.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/47347261705566563/47347261705566563.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 85224,
      "choices": [
        {
          "id": 209390,
          "text": "Endometrioid"
        },
        {
          "id": 209391,
          "text": "Papillary serous"
        },
        {
          "id": 209392,
          "text": "Clear cell carcinoma"
        },
        {
          "id": 209393,
          "text": "Adenosquamous carcinoma"
        }
      ],
      "text": "Most malignant variety of endometrial carcinoma:",
      "unique_key": "Q9999466",
      "question_audio": null,
      "question_video": null,
      "map_id": 34729599,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Clear cell carcinoma Clear cell carcinoma is considered the most malignant variety of endometrial carcinoma. It is a high-grade carcinoma that typically has a poor prognosis due to its aggressive behavior, early spread, and resistance to standard treatments like chemotherapy and radiation. Clear cell carcinoma is often diagnosed at an advanced stage when it has already metastasized to other organs. It is characterized by clear cells due to the accumulation of glycogen or lipids within the cytoplasm and often exhibits solid growth patterns with a high degree of nuclear atypia. This type of carcinoma is relatively rare but more aggressive compared to other forms of endometrial carcinoma. Option A: Endometrioid carcinoma Endometrioid carcinoma is the most common type of endometrial carcinoma and is often associated with unopposed estrogen exposure. While it can present in various grades, it is generally considered less aggressive than other subtypes like clear cell carcinoma or serous carcinoma. Endometrioid carcinoma tends to have a better prognosis when detected early, especially in low-grade forms. High-grade endometrioid carcinomas can still have an aggressive course, but they typically don’t carry the same malignant potential as clear cell carcinoma. Option B: Papillary serous carcinoma Papillary serous carcinoma is another aggressive subtype of endometrial carcinoma but is generally considered slightly less malignant than clear cell carcinoma. It has a poor prognosis due to its tendency to spread early and frequently causes peritoneal metastasis. Papillary serous carcinoma is often diagnosed at advanced stages, and high-grade lesions are associated with a high risk of recurrence. However, clear cell carcinoma is typically regarded as more aggressive due to its resistance to treatment and its tendency to metastasize more rapidly. Option D: Adenosquamous carcinoma Adenosquamous carcinoma is a rare and mixed histological type of endometrial carcinoma that includes both glandular (adenocarcinoma) and squamous differentiation. While it can have a more aggressive course than pure endometrioid carcinoma, it is generally not as malignant as clear cell carcinoma or papillary serous carcinoma. Adenosquamous carcinoma can be associated with a worse prognosis compared to endometrioid carcinoma, but it does not typically have the same degree of aggressive behavior or resistance to treatment as clear cell carcinoma.",
      "correct_choice_id": 209392,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/64393411705566587/64393411705566587.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/64393411705566587/64393411705566587.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 85225,
      "choices": [
        {
          "id": 209394,
          "text": "HRT"
        },
        {
          "id": 209395,
          "text": "Endometrial atrophy"
        },
        {
          "id": 209396,
          "text": "Endometrial cancer"
        },
        {
          "id": 209397,
          "text": "Cervix cancer"
        }
      ],
      "text": "M/C cause of postmenopausal bleeding:",
      "unique_key": "Q4672043",
      "question_audio": null,
      "question_video": null,
      "map_id": 34865674,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Endometrial atrophy Endometrial atrophy is the most common cause of postmenopausal bleeding. As women approach menopause and after they have gone through menopause, the levels of estrogen decrease significantly, leading to thinning and atrophy of the endometrial lining. This thinning can cause irregular shedding of the endometrium, resulting in light spotting or bleeding. The bleeding associated with endometrial atrophy is typically spotting and is usually non-threatening, though it still warrants evaluation to rule out other causes. Endometrial atrophy is a benign condition and is the most likely cause of postmenopausal bleeding in women without other risk factors. Option A: HRT (Hormone Replacement Therapy) Hormone replacement therapy (HRT) can also cause postmenopausal bleeding, but it is not the most common cause. In women who are on HRT, bleeding can occur as a result of the estrogenic effect on the endometrium, which can stimulate endometrial growth. However, this bleeding typically occurs in women who are taking unopposed estrogen or have an inadequate progestogen component in their therapy, which can lead to endometrial hyperplasia and even cancer if not properly managed. While HRT is a potential cause, it is less common than endometrial atrophy as the primary cause of postmenopausal bleeding. Option C: Endometrial cancer Endometrial cancer is a serious and significant cause of postmenopausal bleeding, but it is less common than endometrial atrophy. Although endometrial cancer should always be ruled out in any postmenopausal woman presenting with bleeding, the vast majority of cases of postmenopausal bleeding are due to benign conditions, with endometrial atrophy being the most common. Endometrial cancer typically presents with more persistent and heavy bleeding, and while it is important to investigate any postmenopausal bleeding to rule out cancer, endometrial cancer is a less frequent cause compared to atrophy. Option D: Cervical cancer Cervical cancer is another possible cause of postmenopausal bleeding but is much less common compared to endometrial atrophy. In women with cervical cancer, the bleeding tends to be more irregular and may be associated with other symptoms like pain, discharge, or vaginal masses. While cervical cancer can cause postmenopausal bleeding, its incidence is far lower than that of endometrial atrophy, particularly in the absence of other risk factors like HPV infection or a history of abnormal Pap smears.",
      "correct_choice_id": 209395,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/63576711705566655/63576711705566655.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/63576711705566655/63576711705566655.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 85226,
      "choices": [
        {
          "id": 209398,
          "text": "5%"
        },
        {
          "id": 209399,
          "text": "10%"
        },
        {
          "id": 209400,
          "text": "20%"
        },
        {
          "id": 209401,
          "text": "25%"
        }
      ],
      "text": "Percentage of postmenopausal bleeding patients who have endometrial cancer:",
      "unique_key": "Q6150867",
      "question_audio": null,
      "question_video": null,
      "map_id": 34771035,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) 10% Around 10% of women who experience postmenopausal bleeding will have endometrial cancer. Although postmenopausal bleeding is a concerning symptom, most cases are due to benign conditions, such as endometrial atrophy or hormone replacement therapy. However, approximately 10% of women presenting with postmenopausal bleeding are diagnosed with endometrial cancer. This is why any woman with postmenopausal bleeding should undergo further investigation, such as ultrasound, endometrial biopsy, or dilation and curettage (D&C), to rule out malignancy. Early detection of endometrial cancer is crucial, as the prognosis is generally good when diagnosed in the early stages. Option A: 5% The percentage of endometrial cancer in postmenopausal women presenting with bleeding is higher than 5%. While 5% might seem reasonable in some scenarios, it is an underestimation. As noted, 10% of postmenopausal women with bleeding will have endometrial cancer, meaning 5% would be too low. Option C: 20% A 20% incidence of endometrial cancer in women with postmenopausal bleeding would be too high. Although endometrial cancer is a significant concern, 10% is the typical figure seen in clinical practice. A higher percentage like 20% would suggest a more alarming prevalence of cancer than is commonly observed. Option D: 25% Similarly, 25% would be too high for the incidence of endometrial cancer in women with postmenopausal bleeding. Although it is essential to consider the possibility of cancer, especially if the bleeding persists or is associated with other symptoms, only 10% of these cases will be cancerous. A 25% incidence would indicate a much higher risk of malignancy than is typical.",
      "correct_choice_id": 209399,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/8751601705566675/8751601705566675.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/8751601705566675/8751601705566675.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 85227,
      "choices": [
        {
          "id": 209402,
          "text": "Perform fractional curettage"
        },
        {
          "id": 209403,
          "text": "Perform hysteroscopy and biopsy"
        },
        {
          "id": 209404,
          "text": "Perform pipelle aspiration"
        },
        {
          "id": 209405,
          "text": "Do TAH"
        }
      ],
      "text": "A 52-year-old menopausal female presents with single episode of postmenopausal bleeding. TVS shows endometrial of uniform thickness of 6 mm. What is the most appropriate step in management?",
      "unique_key": "Q4512529",
      "question_audio": null,
      "question_video": null,
      "map_id": 34840454,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Perform pipelle aspiration The most appropriate next step in the management of a 52-year-old menopausal woman with a single episode of postmenopausal bleeding and a 6 mm endometrial thickness on transvaginal ultrasound (TVS) is to perform a pipelle aspiration. The endometrial thickness of 6 mm is within the normal range for postmenopausal women, and a single episode of bleeding is often due to benign causes. A pipelle aspiration is a less invasive procedure that allows for endometrial sampling to rule out endometrial hyperplasia or cancer, and it has a high diagnostic accuracy. If the pipelle biopsy shows any suspicious or abnormal findings, further investigation, such as hysteroscopy, can be performed. This procedure is a quick, effective, and minimally invasive method for obtaining endometrial tissue for histological evaluation. Option A: Perform fractional curettage Fractional curettage is an invasive procedure that involves scraping the endometrium from the uterus. It is typically used in older techniques or when a more extensive tissue sample is needed. However, for a postmenopausal woman with a 6 mm endometrial thickness and a single episode of bleeding, pipelle aspiration is preferred over curettage due to its minimally invasive nature and better patient tolerance. Fractional curettage is not the first-line approach in this case. Option B: Perform hysteroscopy and biopsy Hysteroscopy and biopsy are useful for direct visualization of the uterine cavity and taking tissue samples. However, it is not the first step in the investigation of a 6 mm endometrial thickness with a single episode of bleeding. Hysteroscopy is typically reserved for cases where the pipelle biopsy or other non-invasive tests suggest abnormalities. Since the initial TVS is not alarming, hysteroscopy is not the most appropriate first step. Option D: Do total abdominal hysterectomy (TAH) A total abdominal hysterectomy (TAH) would be an unnecessary and overly aggressive approach for this patient at this stage. A 6 mm endometrial thickness and a single episode of postmenopausal bleeding are not indications for immediate surgery. The initial step should be to rule out malignancy through less invasive methods such as pipelle aspiration or hysteroscopy, rather than proceeding straight to hysterectomy.",
      "correct_choice_id": 209404,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/9217721705566758/9217721705566758.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/9217721705566758/9217721705566758.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 85228,
      "choices": [
        {
          "id": 209406,
          "text": "Cancer cervix"
        },
        {
          "id": 209407,
          "text": "Cancer breast"
        },
        {
          "id": 209408,
          "text": "Cancer ovaries"
        },
        {
          "id": 209409,
          "text": "Cancer endometrium"
        }
      ],
      "text": "Screening is not done for following cancer:",
      "unique_key": "Q3956445",
      "question_audio": null,
      "question_video": null,
      "map_id": 34583356,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Cancer endometrium Cancer endometrium is not routinely screened for in the general population. Unlike cancers of the cervix or breast, there are no standard screening tests for endometrial cancer. Screening for endometrial cancer is generally only recommended for women at high risk, such as those with a history of unopposed estrogen use, obesity, polycycstic ovary syndrome (PCOS), or a family history of Lynch syndrome. As a result, endometrial cancer lacks the same screening protocols as other cancers like cervical or breast cancer. Option A: Cancer cervix Cancer cervix is one of the most well-established cancers for which screening is performed. The Pap smear (or Pap test) and HPV testing are the primary methods used for early detection of cervical cancer. Routine screening of women starting at age 21 and continuing through the age of 65 has been shown to reduce the incidence and mortality of cervical cancer. Therefore, screening for cervical cancer is widely recommended and is not the correct answer. Option B: Cancer breast Cancer breast is another cancer for which routine screening is conducted, primarily through mammograms. Women over the age of 40 are advised to undergo regular mammography screenings to detect breast cancer in its early stages, even before symptoms arise. This is considered an important preventive measure to reduce the risk of late-stage diagnosis. Therefore, breast cancer screening is well-established and is not the correct answer. Option C: Cancer ovaries While there is no consensus on routine screening for ovarian cancer, certain high-risk individuals, such as those with a family history of ovarian or breast cancer or BRCA mutations, may undergo screening using tests like transvaginal ultrasound or CA-125 levels. However, ovarian cancer screening is controversial and is not universally recommended for the general population, unlike cervical or breast cancer screening. That being said, it still has screening measures for high-risk individuals, making it less clear-cut than endometrial cancer, which has no widespread screening.",
      "correct_choice_id": 209409,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/51532181705566775/51532181705566775.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/51532181705566775/51532181705566775.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 85229,
      "choices": [
        {
          "id": 209410,
          "text": "TAH + BSO"
        },
        {
          "id": 209411,
          "text": "TAH + BSO with pelvic lymphadenectomy"
        },
        {
          "id": 209412,
          "text": "TAH + BSO with pelvic and para-aortic lymphadenectomy"
        },
        {
          "id": 209413,
          "text": "TAH + BSO followed by RT"
        }
      ],
      "text": "A 56-year-old female presents with postmenopausal bleeding. A diagnosis of grade II clear cell carcinoma is made. MRI reveals < 50% of myometrial invasion:",
      "unique_key": "Q6837235",
      "question_audio": null,
      "question_video": null,
      "map_id": 34986963,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) TAH + BSO with pelvic and para-aortic lymphadenectomy In the case of clear cell carcinoma of the endometrium with <50% myometrial invasion, the optimal management includes total abdominal hysterectomy (TAH), bilateral salpingo-oophorectomy (BSO), and lymphadenectomy. This includes both pelvic and para-aortic lymphadenectomy. Clear cell carcinoma is an aggressive form of endometrial cancer, and lymphatic spread is common, particularly to the pelvic and para-aortic lymph nodes. Therefore, it is essential to evaluate and remove lymph nodes to assess the extent of spread and improve prognosis. This approach allows for the most thorough staging and increases the chances of optimal treatment and outcome. Option A: TAH + BSO While TAH and BSO are part of the standard surgical treatment for endometrial cancer, this approach alone would not include lymphadenectomy, which is crucial for staging and identifying potential metastasis, especially in cases with clear cell carcinoma, which is known for early spread. Therefore, this option is not sufficient for the given scenario where lymph node involvement must be assessed. Option B: TAH + BSO with pelvic lymphadenectomy This approach includes TAH, BSO, and pelvic lymphadenectomy, but it does not include para-aortic lymphadenectomy. In cases of clear cell carcinoma of the endometrium, the para-aortic lymph nodes can also be involved, especially when there is significant myometrial invasion. Thus, limiting lymphadenectomy to the pelvic region may miss metastases in the para-aortic region, reducing the completeness of staging and treatment. Option D: TAH + BSO followed by RT While radiotherapy (RT) may be part of the adjuvant treatment plan, especially in high-risk cases or those with positive lymph nodes, it is not the first-line treatment after surgery. The primary management involves surgical staging with lymphadenectomy. Radiotherapy is typically considered if there is evidence of residual disease or lymph node involvement post-surgery. This approach would not provide comprehensive staging or lymphatic assessment before considering radiotherapy.",
      "correct_choice_id": 209412,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/13186521705566791/13186521705566791.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/13186521705566791/13186521705566791.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 85230,
      "choices": [
        {
          "id": 209414,
          "text": "Danazol"
        },
        {
          "id": 209415,
          "text": "Cisplatin"
        },
        {
          "id": 209416,
          "text": "Levonorgestrel"
        },
        {
          "id": 209417,
          "text": "Busulfan"
        }
      ],
      "text": "Drug useful in stage III & IV of endometrial cancer:",
      "unique_key": "Q9418764",
      "question_audio": null,
      "question_video": null,
      "map_id": 34247984,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Cisplatin In stage III and IV endometrial cancer, cisplatin, a chemotherapeutic agent, is widely used. It is a platinum-based chemotherapy drug that has proven efficacy in the treatment of advanced or metastatic cancers, including endometrial cancer. Cisplatin works by interfering with the DNA replication of cancer cells, preventing them from dividing and leading to cell death. It is commonly used in combination with other chemotherapy agents to manage advanced stages of endometrial cancer and to improve survival rates. Cisplatin has shown to improve outcomes when used in both the adjuvant setting and in metastatic disease. Option A: Danazol Danazol is an androgenic steroid used in the treatment of endometriosis and certain benign gynecological conditions but is not recommended for the treatment of advanced endometrial cancer. It works by inhibiting estrogen production, which can help manage conditions related to excessive estrogen exposure. However, in stage III and IV endometrial cancer, cisplatin or other chemotherapy agents are preferred for their systemic efficacy in managing metastatic disease, while danazol is not effective in treating cancer of this stage. Option C: Levonorgestrel Levonorgestrel is a progestin often used as a part of hormonal therapy in endometrial cancer but is typically considered in low-grade, early-stage disease or in recurrent disease after surgery. It is not effective for advanced stage cancers, as the cancer in these stages is likely to have developed resistance to hormonal therapy. Cisplatin, being a chemotherapeutic agent, is a more suitable option in advanced stages where surgical or hormonal interventions alone would not suffice. Option D: Busulfan Busulfan is a chemotherapy agent used in certain hematological conditions, particularly in bone marrow suppression or hematopoietic stem cell transplant protocols. It is not used in the treatment of endometrial cancer and does not have a role in managing stage III or IV endometrial cancer. Chemotherapy for advanced endometrial cancer typically involves agents like cisplatin, which has proven efficacy in this setting, rather than busulfan.",
      "correct_choice_id": 209415,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/30507971705566810/30507971705566810.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/30507971705566810/30507971705566810.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 85231,
      "choices": [
        {
          "id": 209418,
          "text": "MSH 3"
        },
        {
          "id": 209419,
          "text": "MSH 6"
        },
        {
          "id": 209420,
          "text": "MLH 1"
        },
        {
          "id": 209421,
          "text": "PMS 1"
        }
      ],
      "text": "Increased risk of endometrial cancer in HNPCC syndrome on Lynch II is M/C associated with alteration in gene:",
      "unique_key": "Q4871537",
      "question_audio": null,
      "question_video": null,
      "map_id": 34450455,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) MLH1 In Hereditary Nonpolyposis Colorectal Cancer (HNPCC), also known as Lynch Syndrome type II, the most commonly affected gene leading to increased risk of endometrial cancer is MLH1. The MLH1 gene is part of the mismatch repair (MMR) system, which helps maintain the stability of the cell's DNA by repairing errors that occur during DNA replication. When mutations occur in MLH1, the DNA mismatch repair process is disrupted, leading to microsatellite instability (MSI) and increased susceptibility to various cancers, including endometrial cancer. This is the most common gene alteration associated with Lynch Syndrome II, which predisposes women to endometrial and ovarian cancers in addition to colorectal cancer. Option A: MSH3 The MSH3 gene is also involved in the mismatch repair (MMR) pathway, but it is less commonly implicated in Lynch Syndrome compared to MLH1. While mutations in MSH3 can contribute to microsatellite instability (MSI) and the development of cancers, they are not as strongly associated with Lynch Syndrome and endometrial cancer as mutations in MLH1. Therefore, MSH3 mutations are not the most common cause of increased endometrial cancer risk in Lynch II syndrome. Option B: MSH6 The MSH6 gene is another mismatch repair gene associated with Lynch syndrome. While mutations in MSH6 can also increase the risk of endometrial cancer, they are less common than mutations in MLH1 in the context of Lynch syndrome. MSH6 mutations typically result in a less aggressive form of the syndrome, and patients with MSH6 mutations tend to develop cancers at an older age, often presenting with colorectal cancer and sometimes endometrial cancer. However, MLH1 mutations are more frequently associated with endometrial cancer risk. Option D: PMS1 The PMS1 gene is also involved in the DNA mismatch repair system, but it is relatively rare as the primary mutation responsible for Lynch syndrome. While PMS1 mutations can contribute to the development of various cancers, including endometrial cancer, they are not the most common alteration seen in Lynch Syndrome II. MLH1 mutations remain the most frequently observed gene alteration associated with increased risk of endometrial cancer in Lynch syndrome.",
      "correct_choice_id": 209420,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/16203101705566825/16203101705566825.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/16203101705566825/16203101705566825.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 85232,
      "choices": [
        {
          "id": 209422,
          "text": "Lymph node status"
        },
        {
          "id": 209423,
          "text": "Ca 125 levels"
        },
        {
          "id": 209424,
          "text": "Histologic variety of tumor"
        },
        {
          "id": 209425,
          "text": "Nutritional status"
        }
      ],
      "text": "In a 65-year-old female with adenocarcinoma of endometrium, the most important prognostic factor is:",
      "unique_key": "Q3980949",
      "question_audio": null,
      "question_video": null,
      "map_id": 34258443,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Histologic variety of tumor The most important prognostic factor in adenocarcinoma of the endometrium is the histologic variety of the tumor. The histologic type and grade of the tumor give insight into its biological behavior, aggressiveness, and likelihood of spread. Endometrial adenocarcinoma can have different histological subtypes, including endometrioid, serous, and clear cell carcinoma, with each having distinct prognostic implications. Endometrioid adenocarcinoma is typically associated with a better prognosis compared to more aggressive subtypes like serous carcinoma, which is known for its poor prognosis and higher likelihood of recurrence and metastasis. The grade of the tumor, which indicates how abnormal the cells appear under a microscope, is also an important determinant of prognosis. High-grade tumors (Grade 3) are more aggressive and have a worse prognosis compared to low-grade tumors (Grade 1). Therefore, the histologic variety and grade of the tumor are critical in determining the patient's overall prognosis and treatment approach. Option A: Lymph node status While lymph node status is an important prognostic factor in many cancers, including endometrial carcinoma, it is not the most important factor in endometrial adenocarcinoma. Although the presence of lymph node involvement is associated with a worse prognosis, histologic variety and grade generally provide more direct and consistent prognostic information, particularly in early-stage disease. Lymph node status is often assessed later during staging or surgery, and its importance is typically secondary to the histologic features in endometrial cancer. Option B: CA 125 levels CA 125 is a tumor marker that can be elevated in endometrial carcinoma and is commonly used to monitor response to treatment or recurrence. However, CA 125 levels are not a primary prognostic factor for endometrial cancer and can be elevated in other conditions, including benign ovarian diseases, other cancers, and even normal conditions. The histologic variety and grade of the tumor provide more specific and reliable prognostic information than CA 125 levels. Option D: Nutritional status While nutritional status is an important factor to consider in the overall health and treatment outcomes of cancer patients, it is not a primary prognostic factor in endometrial cancer. Nutritional status can influence treatment tolerance and recovery, but the key prognostic determinants of survival and recurrence in endometrial cancer are related to factors like histologic variety, grade, and lymph node involvement rather than nutritional status.",
      "correct_choice_id": 209424,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/41364361705566847/41364361705566847.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/41364361705566847/41364361705566847.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 85233,
      "choices": [
        {
          "id": 209426,
          "text": "Simple hyperplasia without atypia"
        },
        {
          "id": 209427,
          "text": "Simple hyperplasia with atypia"
        },
        {
          "id": 209428,
          "text": "Complex hyperplasia without atypia"
        },
        {
          "id": 209429,
          "text": "Complex hyperplasia with atypia"
        }
      ],
      "text": "The risk of endometrial cancer is highest with the following histological pattern of endometrial hyperplasia:",
      "unique_key": "Q3757262",
      "question_audio": null,
      "question_video": null,
      "map_id": 34212200,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Complex hyperplasia with atypia The highest risk of progression to endometrial cancer is associated with complex hyperplasia with atypia. This type of hyperplasia involves abnormal cell growth in the endometrium (the lining of the uterus) and atypia, which refers to abnormal or dysplastic changes in the cells. These changes significantly increase the risk of malignant transformation and endometrial carcinoma. Complex hyperplasia with atypia is considered to be a precancerous lesion because the presence of atypical cells makes it more likely to progress into endometrial carcinoma. Therefore, it is managed aggressively, typically with hormonal therapy or even hysterectomy depending on the patient's age, desire for fertility, and overall health. Option A: Simple hyperplasia without atypia Simple hyperplasia without atypia is considered a low-risk condition for progression to endometrial cancer. This type involves mild overgrowth of the endometrial lining but without the presence of atypical cells. It is typically managed with progestin therapy, which helps regulate the growth of the endometrium and prevent progression to cancer. While the risk of malignancy is low in simple hyperplasia without atypia, it is still important to monitor the patient and ensure that no progression occurs. Option B: Simple hyperplasia with atypia Although simple hyperplasia with atypia presents with atypical cells, it carries a moderate risk of progressing to endometrial cancer. However, it is still not as high-risk as complex hyperplasia with atypia. This condition requires careful monitoring and hormonal treatment to reduce the risk of progression to malignancy, but it is generally less aggressive than complex hyperplasia with atypia. Option C: Complex hyperplasia without atypia Complex hyperplasia without atypia is a condition where there is more glandular overgrowth in the endometrium, but no atypia (abnormal cell changes) are present. While complex hyperplasia without atypia does carry a higher risk than simple hyperplasia without atypia, the absence of atypical cells makes the risk of progression to cancer lower than in cases with atypia. This form of hyperplasia is usually managed with progestin therapy to prevent further hyperplastic changes and reduce the risk of progression.",
      "correct_choice_id": 209429,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/36041881705566867/36041881705566867.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/36041881705566867/36041881705566867.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 85234,
      "choices": [
        {
          "id": 209430,
          "text": "Endodermal sinus tumor"
        },
        {
          "id": 209431,
          "text": "Dysgerminoma"
        },
        {
          "id": 209432,
          "text": "PCOD"
        },
        {
          "id": 209433,
          "text": "Ca cervix"
        }
      ],
      "text": "Endometrial hyperplasia is seen in:",
      "unique_key": "Q3323331",
      "question_audio": null,
      "question_video": null,
      "map_id": 34420527,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) PCOD (Polycystic Ovarian Disease) Polycystic ovarian disease (PCOD) is associated with endometrial hyperplasia due to chronic anovulation and the prolonged exposure of the endometrium to unopposed estrogen. In PCOD, there is often an imbalance in the hormonal regulation, leading to an increase in estrogen levels without the cyclical progesterone that typically follows ovulation. This unopposed estrogen stimulation can result in the thickening of the endometrial lining, leading to endometrial hyperplasia. Endometrial hyperplasia in PCOD can range from simple hyperplasia without atypia to more severe forms with atypia, increasing the risk of endometrial carcinoma if left untreated. Therefore, patients with PCOD should be monitored for endometrial changes, and management may include progestin therapy to reduce the risk of hyperplasia. Option A: Endodermal sinus tumor An endodermal sinus tumor (also known as a yolk sac tumor) is a type of germ cell tumor that typically occurs in the ovary. It is not associated with endometrial hyperplasia. The tumor can cause increased levels of alpha-fetoprotein (AFP), but it does not lead to changes in the endometrium like hyperplasia. Therefore, endodermal sinus tumors are not related to endometrial hyperplasia. Option B: Dysgerminoma A dysgerminoma is a type of germ cell tumor found in the ovaries. It is the ovarian equivalent of seminoma in males. Dysgerminomas do not typically lead to endometrial hyperplasia. While they can cause hormonal changes and occasionally elevated levels of certain markers (such as lactate dehydrogenase), they do not directly cause or contribute to endometrial hyperplasia. Therefore, dysgerminomas are not related to endometrial hyperplasia. Option D: Ca cervix (Cervical cancer) Cervical cancer is caused by persistent infection with high-risk human papillomavirus (HPV). While cervical cancer can affect the reproductive organs, it does not typically cause endometrial hyperplasia. The pathogenesis of cervical cancer is distinct from that of endometrial hyperplasia, and these two conditions do not have a direct causal relationship. Therefore, cervical cancer is not associated with endometrial hyperplasia.",
      "correct_choice_id": 209432,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/48521761705566893/48521761705566893.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/48521761705566893/48521761705566893.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 85235,
      "choices": [
        {
          "id": 209434,
          "text": "Simple hysterectomy"
        },
        {
          "id": 209435,
          "text": "Medroxyprogesterone acetate (MPA)"
        },
        {
          "id": 209436,
          "text": "Levonorgestrel (LNG)"
        },
        {
          "id": 209437,
          "text": "IUCD"
        }
      ],
      "text": "What is the ideal treatment for a 55-year-female with simple hyperplasia of endometrium with atypia?",
      "unique_key": "Q7675145",
      "question_audio": null,
      "question_video": null,
      "map_id": 34642616,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Management of Atypical Endometrial Hyperplasia: \"Hysterectomy is the best treatment for women at any age with atypical endometrial hyperplasia because the risk of concurrent subclinical invasive disease is high.\" \"In presence of atypia, response to progesterone therapy is poor and relapse rate is high. Nearly one-third of them will progress to cancer and one-fourth may already have associated undiagnosed cancer. In women approaching or past menopause, hysterectomy is a safer choice in those with complex or atypical hyperplasia.\"",
      "correct_choice_id": 209434,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/43684561705566912/43684561705566912.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/43684561705566912/43684561705566912.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 85236,
      "choices": [
        {
          "id": 209438,
          "text": "Obesity"
        },
        {
          "id": 209439,
          "text": "Family history"
        },
        {
          "id": 209440,
          "text": "Use of hormone replacement therapy"
        },
        {
          "id": 209441,
          "text": "Early menopause"
        }
      ],
      "text": "All of the following are known risk factors for development of endometrial carcinoma except:",
      "unique_key": "Q9583203",
      "question_audio": null,
      "question_video": null,
      "map_id": 34181681,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Early menopause Early menopause is not a known risk factor for the development of endometrial carcinoma. In fact, early menopause (before the age of 40) typically results in a lower lifetime exposure to estrogen because the hormonal stimulation of the endometrium is reduced. This decrease in estrogen exposure reduces the risk of endometrial hyperplasia and endometrial carcinoma. Early menopause generally lowers the cumulative risk for endometrial cancer due to the reduced length of time the endometrium is exposed to estrogen. Option A: Obesity Obesity is a well-known risk factor for endometrial carcinoma. Adipose tissue is a major source of estrogen production via the aromatization of androgens, which can increase the levels of estrogen in the body. This prolonged exposure to unopposed estrogen stimulates the endometrial lining, which can lead to endometrial hyperplasia and increase the risk of developing endometrial carcinoma. Obesity is a major modifiable risk factor for this cancer. Option B: Family history A family history of endometrial carcinoma or Lynch syndrome (hereditary non-polyposis colorectal cancer, HNPCC) is a known risk factor for the development of endometrial carcinoma. In particular, women with a first-degree relative who had endometrial cancer or a known genetic mutation (such as MLH1, MSH2, or MSH6) are at higher risk for developing this cancer. A family history increases the likelihood of genetic predisposition to endometrial carcinoma. Option C: Use of hormone replacement therapy (HRT) The use of hormone replacement therapy (HRT), particularly unopposed estrogen therapy, is a significant risk factor for the development of endometrial carcinoma. Women who are prescribed estrogen-only therapy without the addition of a progestin (especially those who have an intact uterus) have an increased risk of endometrial hyperplasia, which can progress to cancer. The use of combined estrogen and progestin therapy has a reduced risk of endometrial cancer, but unopposed estrogen significantly elevates the risk.",
      "correct_choice_id": 209441,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/60572141705566929/60572141705566929.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/60572141705566929/60572141705566929.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 85237,
      "choices": [
        {
          "id": 209442,
          "text": "Multiparity"
        },
        {
          "id": 209443,
          "text": "Diabetes mellitus"
        },
        {
          "id": 209444,
          "text": "Hypertension"
        },
        {
          "id": 209445,
          "text": "Obesity"
        }
      ],
      "text": "Which of the following is not seen with corpus cancer syndrome in cancer endometrium?",
      "unique_key": "Q3920632",
      "question_audio": null,
      "question_video": null,
      "map_id": 34819562,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Multiparity Multiparity is not seen as a significant risk factor for corpus cancer syndrome in endometrial cancer. In fact, multiparity (having multiple pregnancies) is generally considered protective against endometrial carcinoma because the hormonal changes during pregnancy, including high levels of progesterone, reduce the number of ovulatory cycles and estrogen exposure to the endometrium, which lowers the risk of developing endometrial cancer. The more pregnancies a woman has, the lower her overall lifetime exposure to unopposed estrogen, which reduces her risk of developing this type of cancer. Option B: Diabetes mellitus Diabetes mellitus is a known risk factor for endometrial carcinoma and is often observed in women with corpus cancer syndrome. Women with type 2 diabetes often experience insulin resistance and elevated insulin levels, which may promote the growth of endometrial cells and increase the risk of endometrial hyperplasia and cancer. The association between diabetes and endometrial carcinoma is likely due to altered hormone levels, including insulin and estrogen, that can increase endometrial cell proliferation. Option C: Hypertension Hypertension is also commonly associated with endometrial carcinoma, especially in the context of corpus cancer syndrome. Hypertension often coexists with other metabolic conditions such as obesity and diabetes, which can contribute to increased estrogen levels and insulin resistance, both of which are risk factors for the development of endometrial cancer. The combination of these metabolic conditions creates an environment that increases the likelihood of endometrial cell hyperplasia and progression to cancer. Option D: Obesity Obesity is a well-established risk factor for endometrial carcinoma and is commonly seen in women with corpus cancer syndrome. Adipose tissue acts as a source of estrogen production due to the conversion of androgens to estrogens in fat cells. Elevated estrogen levels without the balancing effect of progesterone can lead to endometrial hyperplasia and increase the risk of endometrial carcinoma. Obesity is a major modifiable risk factor for this type of cancer.",
      "correct_choice_id": 209442,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/4357921705566943/4357921705566943.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/4357921705566943/4357921705566943.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 85238,
      "choices": [
        {
          "id": 209446,
          "text": "Ill A"
        },
        {
          "id": 209447,
          "text": "Ill B"
        },
        {
          "id": 209448,
          "text": "Ill C1"
        },
        {
          "id": 209449,
          "text": "IIIC2"
        }
      ],
      "text": "A lady presented with carcinoma endometrium involving >50% of myometrium extending to vagina and positive peritoneal cytology but no involvements of para aortic and preaortic nodes. What is the stage of disease?",
      "unique_key": "Q8582999",
      "question_audio": null,
      "question_video": null,
      "map_id": 34828311,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) III B The correct stage of disease in this scenario is Stage III B. According to the FIGO staging system for endometrial cancer, Stage III includes tumors that have extended beyond the uterus but have not spread to distant organs. In Stage III B, the cancer involves the vagina and/or the parametrium (tissues surrounding the uterus), but not the lymph nodes. The patient described has cancer involving more than 50% of the myometrium, extending into the vagina, and has positive peritoneal cytology, but no involvement of the para-aortic and pre-aortic nodes. The peritoneal cytology being positive, despite the lack of lymph node involvement, classifies this as Stage III B. Option A: III A Stage III A involves the myometrium and extends into the serosa of the uterus, but without involvement of the vagina, parametrium, or lymph nodes. The involvement of the vagina in this case excludes Stage III A. Option C: III C1 Stage III C1 refers to the involvement of pelvic lymph nodes. Since this patient has no involvement of the pelvic lymph nodes, Stage III C1 is incorrect. The patient’s positive peritoneal cytology and vaginal extension make Stage III C1 unfit as the correct diagnosis. Option D: III C2 Stage III C2 refers to para-aortic lymph node involvement. However, in this case, there is no involvement of para-aortic or pre-aortic nodes, thus making Stage III C2 inappropriate.",
      "correct_choice_id": 209447,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/26052511705566970/26052511705566970.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/26052511705566970/26052511705566970.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 85239,
      "choices": [
        {
          "id": 209450,
          "text": "Radiotherapy"
        },
        {
          "id": 209451,
          "text": "Chemotherapy"
        },
        {
          "id": 209452,
          "text": "Chemotherapy + Radiotherapy"
        },
        {
          "id": 209453,
          "text": "No treatment"
        }
      ],
      "text": "Choice of adjuvant treatment for endometrial carcinoma stage I A grade I is:",
      "unique_key": "Q8483395",
      "question_audio": null,
      "question_video": null,
      "map_id": 34335116,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) No treatment In the case of endometrial carcinoma stage I A grade I, the tumor is localized to the endometrium, with no deep myometrial invasion or lymph node involvement. Stage I A represents a very early-stage disease with a favorable prognosis, and grade I indicates a well-differentiated tumor (low grade). Because of the favorable prognosis, adjuvant treatment (such as radiotherapy, chemotherapy, or a combination of both) is typically not necessary. These patients are generally managed with surgical staging, which usually includes a total hysterectomy and bilateral salpingo-oophorectomy (BSO). Observation or follow-up without additional treatment is the standard of care, given the low risk of recurrence in this stage and grade. Option A: Radiotherapy Radiotherapy is typically considered in cases of higher-stage or higher-grade endometrial carcinoma to reduce the risk of local recurrence, particularly if there is deep myometrial invasion or lymphovascular space invasion (LVSI). However, Stage I A grade I endometrial carcinoma has a low risk of local recurrence, making radiotherapy unnecessary in this case. Option B: Chemotherapy Chemotherapy is usually reserved for more advanced-stage or higher-grade endometrial carcinomas, particularly those with lymph node involvement, deep myometrial invasion, or peritoneal spread. It is not indicated for Stage I A grade I endometrial carcinoma due to its low risk of recurrence. Option C: Chemotherapy + Radiotherapy Combining chemotherapy and radiotherapy is generally reserved for more advanced stages or high-risk features, such as Stage III or Stage IV disease or higher-grade tumors. For a Stage I A grade I tumor, this aggressive approach is not warranted due to the excellent prognosis associated with this early-stage, low-grade cancer.",
      "correct_choice_id": 209453,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/71239821705567006/71239821705567006.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/71239821705567006/71239821705567006.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 85240,
      "choices": [
        {
          "id": 209454,
          "text": "Hysterectomy"
        },
        {
          "id": 209455,
          "text": "Start progesterone therapy"
        },
        {
          "id": 209456,
          "text": "Histopathological examination of curettage"
        },
        {
          "id": 209457,
          "text": "Follow up sonography"
        }
      ],
      "text": "A 45 year old post menopausal women presents with vaginal bleeding transvaginal ultrasound reveals are endometrial thickness of 8.0 mm the next step is the management should be :",
      "unique_key": "Q6948733",
      "question_audio": null,
      "question_video": null,
      "map_id": 34459281,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Histopathological examination of curettage In a postmenopausal woman presenting with vaginal bleeding, an endometrial thickness of 8.0 mm on transvaginal ultrasound is concerning. While endometrial thickness in postmenopausal women should generally be < 5 mm, a thickness of 8 mm raises the possibility of endometrial hyperplasia or endometrial carcinoma. The next step in management is to perform a d&C (dilation and curettage) or pipelle aspiration for histopathological examination to evaluate the endometrial tissue. This will help to determine whether there is hyperplasia (with or without atypia), endometrial carcinoma, or other causes of bleeding. Based on the histopathological findings, appropriate treatment can be initiated. Option A: Hysterectomy Hysterectomy may be considered if endometrial carcinoma is diagnosed, or if the bleeding persists despite other treatments, or if the patient has high-risk factors. However, it is not the first-line management for postmenopausal bleeding with an endometrial thickness of 8 mm. A histopathological examination is essential to determine the underlying cause before deciding on surgical options. Option B: Start progesterone therapy Starting progesterone therapy might be appropriate if endometrial hyperplasia without atypia is diagnosed, as progesterone can help to reduce the endometrial thickness and reverse hyperplasia. However, histopathological examination is required to rule out malignancy or more severe forms of hyperplasia before starting any treatment like progesterone. Therefore, starting progesterone therapy without confirming the diagnosis is not recommended. Option D: Follow-up sonography While follow-up sonography might be useful in some cases to monitor the endometrial thickness over time, it is not sufficient as the next step in management. Vaginal bleeding in a postmenopausal woman requires immediate further investigation, including histopathological evaluation to rule out any serious conditions like endometrial carcinoma or severe hyperplasia. Delaying diagnosis through follow-up imaging could delay necessary treatment.",
      "correct_choice_id": 209456,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/48593191705572519/48593191705572519.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/48593191705572519/48593191705572519.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 85241,
      "choices": [
        {
          "id": 209458,
          "text": "Myomectomy"
        },
        {
          "id": 209459,
          "text": "Total abdominal hysterectomy"
        },
        {
          "id": 209460,
          "text": "Oral contraceptives"
        },
        {
          "id": 209461,
          "text": "Uterine artery embolization"
        },
        {
          "id": 209462,
          "text": "Oral progesterone"
        }
      ],
      "text": "A 57-year-old menopausal patient presents to your office for evaluation of postmenopausal bleeding. She is morbidly obese and has chronic hypertension and adult onset diabetes. An endometrial sampling done in the office shows complex endometrial hyperplasia with atypia. Which of the following is the best treatment option for this patient?",
      "unique_key": "Q7341404",
      "question_audio": null,
      "question_video": null,
      "map_id": 34848402,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Total abdominal hysterectomy. The patient has complex endometrial hyperplasia with atypia, which is a precursor lesion for endometrial carcinoma. The presence of atypia indicates a significantly increased risk of progression to malignancy. The most definitive and curative treatment for complex endometrial hyperplasia with atypia, particularly in a postmenopausal woman, is total abdominal hysterectomy. This procedure removes the uterus, thus eliminating the risk of progression to endometrial cancer and providing a definitive treatment for this condition. Since the patient is postmenopausal and has significant risk factors, a hysterectomy is the best choice to ensure complete removal of the abnormal tissue. Why the other options are incorrect: A. Myomectomy: A myomectomy is a surgical procedure used to remove fibroids from the uterus. It is not appropriate for treating endometrial hyperplasia with atypia, which is a different condition involving the endometrial lining rather than fibroids. This option would not address the patient's underlying pathology, which has a risk of malignancy. C. Oral contraceptives: Oral contraceptives are used for managing conditions like irregular menstruation or to prevent pregnancy. However, they are not effective in treating endometrial hyperplasia with atypia. Atypical hyperplasia carries a high risk of developing into cancer, and oral contraceptives do not provide the level of intervention necessary for this high-risk condition. More aggressive treatment, like hysterectomy, is needed. D. Uterine artery embolization: Uterine artery embolization is used for managing uterine fibroids by cutting off blood supply to the fibroids. It is not indicated for treating endometrial hyperplasia with atypia. Since the condition involves abnormal proliferation of the endometrial lining, a hysterectomy is a more appropriate option. E. Oral progesterone: Oral progesterone can be used to treat simple endometrial hyperplasia without atypia by inducing regression of the hyperplastic endometrial tissue. However, in the presence of atypia, the risk of progression to carcinoma is much higher. Although oral progesterone may reduce the hyperplasia, it does not guarantee that the atypia will be resolved, and it carries a risk of progression to cancer. A hysterectomy is the preferred treatment for atypical hyperplasia in postmenopausal women due to the higher risk of malignancy.",
      "correct_choice_id": 209459,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/22219181705572766/22219181705572766.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/22219181705572766/22219181705572766.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 85242,
      "choices": [
        {
          "id": 209463,
          "text": "Chronic anovulation"
        },
        {
          "id": 209464,
          "text": "Obesity"
        },
        {
          "id": 209465,
          "text": "Multiparity"
        },
        {
          "id": 209466,
          "text": "Late menopause"
        }
      ],
      "text": "High risk for endometrial intraepithelial neoplasia (EIN) or carcinoma include all of the following except:",
      "unique_key": "Q2076142",
      "question_audio": null,
      "question_video": null,
      "map_id": 34310010,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Multiparity. Multiparity, or having multiple pregnancies, is not considered a risk factor for endometrial intraepithelial neoplasia (EIN) or endometrial carcinoma. In fact, multiparity is often associated with a lower risk of developing endometrial cancer, as pregnancy and childbirth are protective factors. This is due to the hormonal changes during pregnancy, such as high levels of progesterone, which reduce the risk of endometrial hyperplasia and carcinogenesis. Therefore, the correct answer is C, as multiparity is not a high-risk factor for EIN or endometrial carcinoma. Why the other options are incorrect: A. Chronic anovulation: Chronic anovulation is a significant risk factor for developing endometrial intraepithelial neoplasia and carcinoma. Anovulation leads to unopposed estrogen exposure, which stimulates the endometrium and increases the risk of hyperplasia and cancer. Without ovulation, there is no progesterone to counterbalance estrogen, leading to endometrial overgrowth. This makes chronic anovulation a high-risk condition for developing EIN or endometrial cancer. B. Obesity: Obesity is a well-established risk factor for endometrial intraepithelial neoplasia and carcinoma. Excess body fat increases the production of estrogen, which is converted from androgens in adipose tissue. This elevated estrogen level, particularly in postmenopausal women, can stimulate the endometrium, leading to hyperplasia and an increased risk of developing endometrial carcinoma. D. Late menopause: Late menopause is another risk factor for endometrial carcinoma. Women who experience menopause later than usual have prolonged exposure to estrogen, as the ovaries continue to produce estrogen until menopause. This prolonged estrogen exposure without the counterbalancing effects of progesterone increases the risk of endometrial hyperplasia and carcinoma.",
      "correct_choice_id": 209465,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/27030541705572846/27030541705572846.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/27030541705572846/27030541705572846.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 85243,
      "choices": [
        {
          "id": 209467,
          "text": "Estriol"
        },
        {
          "id": 209468,
          "text": "Estradiol"
        },
        {
          "id": 209469,
          "text": "Estrone"
        },
        {
          "id": 209470,
          "text": "Androstenedione"
        }
      ],
      "text": "A 36-year-old morbidly obese woman presents to your o?ce for evaluation of irregular, heavy menses occurring every 3 to 6 months. An o?ce endometrial biopsy shows complex hyperplasia of the endometrium without atypia. The hyperplasia is most likely related to the excess formation in the patient’s adipose tissue of which of the following hormones?",
      "unique_key": "Q9194608",
      "question_audio": null,
      "question_video": null,
      "map_id": 34808724,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Estrone In a morbidly obese woman, the most likely cause of complex hyperplasia of the endometrium without atypia is the excess formation of estrone in the adipose tissue. Estrone is the primary estrogen produced in postmenopausal women and in women with obesity, as adipose tissue has the ability to convert androstenedione (a steroid produced by the adrenal glands) into estrone through the action of the enzyme aromatase. In obesity, this process is more pronounced due to the higher amounts of adipose tissue, which leads to elevated levels of estrone. This increase in estrone stimulates the endometrial lining, resulting in endometrial hyperplasia. The absence of atypia suggests that the hyperplasia is less likely to be malignant at this stage. Option A: Estriol Estriol is a weaker estrogen produced primarily during pregnancy by the placenta, and its levels are not significantly affected by obesity. It is not a significant contributor to endometrial hyperplasia in the context of obesity. Therefore, estriol is an unlikely cause of the patient's complex hyperplasia. Option B: Estradiol Estradiol is the most potent estrogen and is primarily produced by the ovaries, particularly in the reproductive years. While estradiol can contribute to endometrial hyperplasia, the patient’s irregular menses, combined with her morbid obesity, points more toward the conversion of androstenedione to estrone in adipose tissue rather than direct estradiol secretion from the ovaries. Therefore, estradiol is less likely to be the primary hormone involved in this case compared to estrone. Option D: Androstenedione Androstenedione is an adrenal steroid that is a precursor to both estrone and testosterone. While androstenedione is converted into estrone in adipose tissue, it is not the primary hormone responsible for the development of endometrial hyperplasia in this scenario. The conversion to estrone is the key factor here, rather than the direct effect of androstenedione.",
      "correct_choice_id": 209469,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/70662251705572994/70662251705572994.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/70662251705572994/70662251705572994.m3u8",
      "question_images": [],
      "explanation_images": []
    }
  ]
}